19.04.2017

The Russian Society of Obstetricians and Gynecologists (RSOG) led by Acad. v. N. Serov, sponsored by Petrovax Pharm, pursues a unique project, i.e. the All-Russia contest of clinical observations of Longidaze use .

Any Russian obstetrician-gynecologist whose work is directly related to the clinical observations in question may take part in the contest.

The entry works should be related to Longidaze® (bovhualuronidase azoximer) application in pelvic inflammatory diseases, endometriosis, tubal-peritoneal infertility, and other disorders associated with connective tissue hyperplasia for adhesion disease prevention or treatment.

The contest duration is early April — September. The physicians filing the best cases will win the recognition among the colleagues and awards.

The award ceremony will be held within the framework of the annual all-Russia scientific and educational forum «Mother and Child» (September 27–29, Moscow).

For more details, please go to the RSOG website: www.roagkonkurs.ru

Longidaze is an advanced sustained release enzyme for combined therapy of connective tissue hyperplasia diseases (adhesion, scarring, or fibrous processes). This product has been successfully used in gynecology for 10 years, and due to its broad therapeutic indication spectrum, physicians have gained vast experience of its clinical use that they can share with the scientific community at large and their colleagues.


Back to the list